ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Thomas Egan
Thomas M. Egan, M.D. M.Sc.
Background
University of Toronto (MD 1976)
York Finch Hospital Rotating Internship (1976-1977)
Medical Officer & Flight Surgeon, Canadian Armed Forces Base Chatham NB (1977-1980)
University of Toronto General Surgery Residency (1980-1986)
University of Toronto (MSc 1984)
University of Toronto Residency in Cardiovascular and Thoracic Surgery (1986-1988)
Washington University Thoracic Transplant Fellow (1988-1989)
Faculty, UNC Chapel Hill (1989-present)
Other Interests
Due to an ambulatory disability, I no longer perform surgery
Lung Transplantation
Ischemic Lung Injury
Lung Transplantation from non-heart-beating donors
Organ Allocation for Transplant
Quantitative Lung Ultrasound
Hydrogel patches for drug delivery to organs
Photography
Research
The lung doesn't die when you do. Lung cells do not rely on blood perfusion for cellular respiration. So lung cells live for hours after circulatory arrest and deah of an individual. Our lab has shown that lungs could be transplanted with good function if recovered one hour after death from non-ventilated deceased donors. Duration of tolerable ischemia could be enhanced by ventilation of a deceased animal with oxygen. In subsequest studies we showed that oxygen ventilation of a dead animal was associated with delayed lung parenchymal cell death, ultrasructural integrity, and maintenance of total adenine nucleotide levels. We used ex-vivo lung perfusion (EVLP) to evaluate lungs recovered from uncontrolled Donation after Circulatory Death Donors (uDCDs), formerly known as Maastricht Category 1 & 2 non-heart-beating donors. I had IRB and FDA approval to offer suitable lungs for transplant. Funding was withdrawn because of failure to meet ambitious milestones. We have translational rat lung transplant and rat lung EVLP circuits, and cell culture models of lung IRI. We have developed a mouse lung transplant model, and have performed EVLP and transplant of swine lungs in a brain-dead donor model. I have collaborated with an acoustic scientist at NC State University on the new field of quantitative lung ultrasound (QLUS). We showed that lung ultrasound multiple scattering (USMS) can be used to quantify severity of lung edema and pulmonary fibrosis. By mapping areas where USMS does not occur, we can use QLUS to localize pulmnary nodules, and their relationship to surgcal staplers. I have slso collaborated with a pharmacist who has developed novel hydrogel patches that stretch with organs that move (lung, heart, bladder, blood vessels) for delivery of therapeutics or exosomes containing human bone-marrow derived stem cells. I am interested in ethical issues surrounding organ transplant. I chaired the lung allocation subcommmittee of the OPTN thoracic organ committee and helped introduce the Lung Allocation Score into lung transplant.
Practice Areas
- Thoracic
